Clinical trials: Acquired Immunodeficiency Syndrome
HIV
HIV Prevention Toolkit for HIV-negative Male Couples
Though technology is integrated into the lives of our target population, use of any particular technology will depend on the content delivered, aesthetic appeal, and overall design.
- Trial name
- MCAP (NCT02494817)
- Testing
- Male Couples Agreement Project
- Where
- United States
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- University of Miami
Body Image Disturbance, Medication Adherence
Body Image and Self-Care in HIV-Infected MSM
The purpose of this study is to develop and test counseling strategies for men who have sex with men (MSM) who are living with HIV and are experiencing body dissatisfaction.
- Trial name
- BUILD (NCT01817621)
- Testing
- Experimental Intervention, TAU
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Massachusetts General Hospital
HIV Infections
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in children living with HIV less than 12 years of age.
- Trial name
- NCT03760458
- Testing
- Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
- Where
- 14 sites in United States, Botswana and 2 more
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Immunogenicity of COVID-19 Vaccination in PLWH
Various facts support the study of COVID-19 vaccine immunogenicity in People Living With HIV (PLWH) at this time: (1) Many PLWH in Canada will be eligible to receive COVID-19 vaccination as they are in a high priority risk group…
- Trial name
- HIV-COV (NCT04894448)
- Testing
- COVID-19 Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- CIHR Canadian HIV Trials Network
HIV/AIDS Treatment, HIV Infections
Lopinavir/Ritonavir (Kaletra) PK in Children
The objective of this study is to compare the pharmacokinetics of lopinavir tablets administered to pediatric patients as either whole or crushed tablets.
- Trial name
- NCT00810108
- Testing
- lopinavir/ritonavir (Kaletra®) tablets
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
HIV/AIDS
Improving Health Outcomes for Women Living With HIV
This study will develop and conduct a trans-specific peer navigation intervention in Brazil, which integrates the I-Care approach developed in South Africa with the Model of Gender Affirmation (GA), developed by the investigators…
- Trial name
- NCT03525340
- Testing
- Peer Navigation
- Where
- Brazil
- Volunteers
- 113 people
- Sponsor
- University of California, San Francisco
HIV Infection
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services.
- Trial name
- NCT02302950
- Testing
- raltegravir
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV Infections, Coronary Disease
HIV&HEART Aging Study (12,5 Year Follow up)
The HIV/HEART Aging study (HIVH) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (CVD) in HIV-infected patients.
- Conditions
- HIV Infections, Coronary Disease, Myocardial Infarction, HIV Encephalopathy
- Trial name
- HIV&HEART (NCT04156048)
- Where
- 6 sites in Germany
- Volunteers
- 1,809 people
- Sponsor
- University Hospital, Essen
HIV Infection
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among…
- Trial name
- NCT02140255
- Testing
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r)
- Where
- 47 sites in United States, Argentina and 11 more
- Volunteers
- 1,120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Adaptation and Evaluation of an Intersectional Stigma Reduction Intervention to Increase HIV Care Engagement Among Women Who Use Drugs
The goal of this study is to test whether a program reduce stigma will help women living HIV remain in HIV care.
- Trial name
- Light Inside (NCT07751978)
- Testing
- Light Inside, standard of care
- Where
- Ukraine
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection.
- Trial name
- NCT00002150
- Testing
- Celgosivir hydrochloride
- Where
- 23 sites in United States
- Volunteers
- 200 people
- Sponsor
- Hoechst Marion Roussel
HIV Infections
A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
The purpose of this study is to determine the safety and maximum tolerated dose (the highest dose that can be given safely) of recombinant Interleukin-2 (rIL-2) in HIV-infected children.
- Trial name
- NCT00000849
- Testing
- Aldesleukin
- Where
- 14 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, HIV Infections
Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
This study evaluated the safety, tolerability, and pharmacokinetics of the anti-tuberculosis (TB) drugs bedaquiline (BDQ) and delamanid (DLM), alone and in combination, among participants (with or without HIV co-infection) taking…
- Trial name
- NCT02583048
- Testing
- Bedaquiline, Delamanid, Dolutegravir
- Where
- 3 sites in Peru, South Africa
- Volunteers
- 84 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
To determine the safety of intravenous infusion of ampligen in symptomatic HIV-infected patients at several dose levels, to determine the maximum dose that can be tolerated, and to measure the effects of ampligen on the HIV virus…
- Trial name
- NCT00000735
- Testing
- Ampligen
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kaposi´s Sarcoma
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi sarcoma remains the most common malignancy among persons with HIV. Lesions localized to the airway may cause bleeding, pain and dyspnea. New therapeutic approaches for local disease are needed.
- Trial name
- NCT01296815
- Testing
- Bevacizumab
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
Alcohol Drinking, Alcohol; Harmful Use
Alcohol and Immune Response
This study investigates how alcohol affects the immune system and behavior in healthy adults. The study also will examine how an individual's typical drinking habits may affect the immune system's response to alcohol.
- Trial name
- NCT03483389
- Testing
- Alcohol, Ethyl
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Brown University
HIV Infections, HIV Seronegativity
ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
The purpose of this study is to test how the body's immune system responds to the vaccine ALVAC-HIV vCP1452 and to determine if the vaccine is safe when given alone and with MN rgp120.
- Trial name
- NCT00011037
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1
- Where
- 4 sites in Brazil, Haiti and 2 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
The purpose of this research study is to evaluate how easy it is for female HIV- positive subjects taking Complera to comply with the dietary requirement using a food diary in the short term (4 weeks) and long term (24 weeks and…
- Trial name
- NCT01701895
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Prema Menezes, PhD, PA-C
HIV, Hepatitis E
Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
Study of seroprevalence of hepatitis E among HIV positive patient in Basque country, France in 2016.
- Trial name
- VIhVhEpb (NCT02847507)
- Where
- France
- Volunteers
- 307 people
- Sponsor
- Centre Hospitalier de la côte Basque
HIV Infections, Chronic Hepatitis B
Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection
This study will evaluate the safety and effectiveness of adefovir plus lamivudine for chronic hepatitis B infection in people with and without HIV infection.
- Trial name
- NCT00023153
- Testing
- Adefovir Dipivoxil
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.